Sellas Life Sciences Group Inc. – Capital Raise Amid Breakthrough AML Vaccine Data

Sellas Life Sciences Group Inc. (NASDAQ: SLS), a New York‑based biotechnology company focused on late‑stage oncology therapeutics, announced on 17 November 2026 that it will conduct a $150 million underwritten public offering. The announcement, reported by Investing.com, GlobeNewswire, and CEO.ca, follows a landmark clinical success for the company’s lead asset, galinpepimut‑S (GPS), an off‑the‑shelf cancer vaccine targeting acute myeloid leukemia (AML).

Vaccine Milestone and Market Impact

Bloomberg reported that GPS achieved a 41 % reduction in mortality versus the best available treatment, with a median overall survival of 24 months compared to less than 15 months for standard therapies. The data were generated in a phase‑III trial and led to a 233 % intraday rally in Sellas shares, the largest single‑day gain on record for the stock. Analyst James Molloy of Alliance Global Partners noted that the results “could usher in a new treatment option” for AML patients and, if approved, position GPS as a potential standard of care.

The announcement has also amplified investor enthusiasm, as reflected in coverage on Invezz.com that highlighted the over 220 % surge in share price. Short interest had previously climbed to 29 % of freely tradable shares, underscoring a notable shift in market sentiment following the data release.

Financing Strategy and Capital Deployment

The $150 million offering is intended to provide Sellas with the resources needed to:

  1. Advance regulatory submissions for GPS in the United States and internationally.
  2. Scale up manufacturing to meet projected commercial demand.
  3. Support the development of additional pipeline candidates within the company’s oncology portfolio.

Given the company’s market cap of approximately $1.52 billion and a trailing close price of $7.47 on 15 November 2026, the offering represents a significant capital infusion that will likely dilute existing shareholders but is expected to underpin long‑term growth.

Financial Position and Outlook

With a price‑earnings ratio of –38.39, Sellas remains a high‑growth, pre‑profit entity. The recent trial success, however, has sharpened expectations for a near‑term shift toward positive earnings as the company moves closer to product launch. The stock’s 52‑week range (high of $15.88 on 29 June 2026 and low of $1.39 on 1 December 2025) reflects a volatile but ultimately upward trajectory driven by clinical milestones.

Conclusion

Sellas Life Sciences Group’s timely capital raise, coupled with breakthrough data for its lead AML vaccine, positions the company at a pivotal juncture. The infusion of $150 million will accelerate regulatory and commercial milestones, potentially transforming GPS from a clinical success into a revenue‑generating therapy. Market participants are watching closely as the company navigates the next phases of development and commercialization, with the potential to redefine treatment paradigms for acute myeloid leukemia.